2. Search Result
Search Result
Results for "

electroshock

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-172431
    Opakalim

    BHV-7000

    		 Potassium Channel Neurological Disease
    Opakalim (BHV-7000) is a selective Kv7.2/7.3 potassium channels activator with an EC50 of 0.6 μM. Opakalim shows minimal GABAA receptor activation and exhibits potent anti-seizure efficacy in the maximal electroshock seizure (MES) model. Opakalim can be used for the study of seizures .
    Opakalim
  • HY-168773
    (R)-AS-1

    		EAAT Neurological Disease
    (R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .
    (R)-AS-1
  • HY-B1730
    Phensuximide
    2 Publications Verification

    		 Cyclic GMP-AMP Synthase Neurological Disease Metabolic Disease
    Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide
  • HY-123671
    CYM2503

    		Neuropeptide Y Receptor Neurological Disease
    CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .
    CYM2503
  • HY-W012481
    Nirvanol

    Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin

    		 Drug Metabolite Neurological Disease
    Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
    Nirvanol
  • HY-133486
    GABAA receptor agent 1

    		GABA Receptor Neurological Disease
    GABAA receptor agent 1 is a high affinity ligand for GABAA receptor, with potent anticonvulsant activity .
    GABAA receptor agent 1
  • HY-W322222
    Ethyl (E,Z)-2,4-decadienoate

    		Sex Pheromone Endocrinology
    Ethyl (E,Z)-2,4-decadienoate is a pheromone that induces an electroshock response in male cold moths (Sensilla Auricillica) and can be isolated from host plants .
    Ethyl (E,Z)-2,4-decadienoate
  • HY-W681659
    Flutoprazepam

    KB-509

    		 GABA Receptor Neurological Disease
    Flutoprazepam (KB-509), a benzodiazepine drug, possesses anticonflict effect. Flutoprazepam (KB-509) prevents maximal electroshock, pentetrazol, and strychnine-induced convulsions in mice .
    Flutoprazepam
  • HY-100377
    Lvguidingan

    Anticonvulsant 7903

    		 Others Neurological Disease
    Lvguidingan is a potent anticonvulsant agent. Lvguidingan also has sedative-hypnotic, tranquilizing, and muscle-relaxing actions. Lvguidingan can be used as antiepileptic agent .
    Lvguidingan
  • HY-W097106
    (S)-3-N-Cbz-Amino-succinimide

    		Drug Isomer Neurological Disease
    (S)-3-N-Cbz-Amino-succinimide (Compound 1d) is an antiepileptic agent that can inhibit pentylenetetrazole (PTZ) and maximal electroshock (MES)-induced tonic convulsions in mice .
    (S)-3-N-Cbz-Amino-succinimide
  • HY-W012481R
    Nirvanol (Standard)

    Ethylphenylhydantoin (Standard); Phenylethyihydantoin (Standard); Desmethylmephenytoin (Standard)

    		 Drug Metabolite Reference Standards Neurological Disease
    Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
    Nirvanol (Standard)
  • HY-106424
    Soretolide

    		Drug Intermediate Neurological Disease
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model .
    Soretolide
  • HY-170833
    Anticonvulsant agent 8

    		GABA Receptor Neurological Disease
    Anticonvulsant agent 8 (compound D4) is an anticonvulsant agent that inhibits GABAA currents with ED50 values of 2.23 and 24.60 mg/kg in the maximum electroshock (MES) and pentylenetetrazol (PTZ) tests in mouse models, respectively .
    Anticonvulsant agent 8
  • HY-173616
    GABAA receptor modulator-8

    		GABA Receptor Neurological Disease
    GABAA receptor modulator-8 (10c) is a blood-brain barrier penetrated, selective and positive modulator of GABAA receptor, with excellent antiepileptic activity .
    GABAA receptor modulator-8
  • HY-W012481S
    Nirvanol-d5

    Ethylphenylhydantoin-d5; Phenylethyihydantoin-d5; Desmethylmephenytoin-d5

    		 Isotope-Labeled Compounds Drug Metabolite Neurological Disease
    Nirvanol-d5 (Ethylphenylhydantoin-d5) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
    Nirvanol-d5
  • HY-148135
    hCAI/II-IN-6

    		Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-172887
    Kv7.2/Kv7.3 activator-2

    		Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC50: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .
    Kv7.2/Kv7.3 activator-2
  • HY-178016
    H3R antagonist 8

    		Histamine Receptor Neurological Disease
    H3R antagonist 8 is a selective nonimidazole histamine H3 receptor antagonist (IC50 = 0.35 μM). H3R antagonist 8 exhibits hERG channel blockade activity (IC50 = 0.67 μM). H3R antagonist 8 inhibits seizures by antagonizing H3 receptor. H3R antagonist 8 reduces tonic hind limb extension (THLE) in mice in the maximal electroshock seizure (MES) model (ED50 = 20.21 mg/kg) and and shortens pentylenetetrazol (PTZ)-induced total movement distance in AB strain zebrafish larvae. H3R antagonist 8 can be used for the study of epilepsy .
    H3R antagonist 8
  • HY-B1730R
    Phensuximide (Standard)

    		Cyclic GMP-AMP Synthase Reference Standards Neurological Disease Metabolic Disease
    Phensuximide (Standard) is the analytical standard of Phensuximide. This product is intended for research and analytical applications. Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide (Standard)
  • HY-170801
    Anticonvulsant agent 7

    		Drug Derivative Neurological Disease
    Anticonvulsant agent 7 (Compound 19) is an orally active broad-spectrum anticonvulsant that demonstrates excellent anticonvulsive activity in both the MES (maximal electroshock seizure) and 6 Hz epilepsy modelsmouse .
    Anticonvulsant agent 7
  • HY-114833
    Bunolol

    (Rac)-Bunolol; dl-Bunolol

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Bunolol ((Rac)-Bunolol) is a β-adrenergic receptor blocker. Bunolol antagonizes the β-receptor agonist activity induced by Isoproterenol (HY-B0468) and Dichloroisoproterenol. Bunolol reduces the heart rate and mean blood pressure of anesthetized dogs. Bunolol decreases spontaneous motor activity and Amphetamine-induced hyperactivity in rats, potentiates Pentobarbital-induced hypnosis in mice, and protects rats from extensor tonic convulsions induced by maximal electroshock .
    Bunolol
  • HY-W550494
    1-(Pyridin-4-yl)heptan-1-one

    		Others Neurological Disease
    1-(Pyridin-4-yl)heptan-1-one (Compound R=n-C₆H₁₃) is an anticonvulsant agent. 1-(Pyridin-4-yl)heptan-1-one can protect mice from electroshock-induced convulsions. 1-(Pyridin-4-yl)heptan-1-one is promising for research of convulsion-related diseases such as epilepsy .
    1-(Pyridin-4-yl)heptan-1-one
  • HY-15080
    GYKI 53405

    LY 293606

    		 iGluR Cardiovascular Disease Neurological Disease
    GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
    GYKI 53405
  • HY-119716
    Cyheptamide

    		Neurological Disease
    Cyheptamide is an orally active anticonvulsant and antiepileptic agent. Cyheptamide exhibits moderate acute toxicity in animal models, with lethal doses varying by species specificity. Cyheptamide can be used in studies related to convulsions and epilepsy .
    Cyheptamide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: